worth a read..15 Oct 2018 13:34
I look forward to the“successful crystallisation of substantial value for patients and shareholders”, Dr Satu Vainikka, ValiRX CEO.1
“The company has seen considerable progress across our therapeutic portfolio in the last six months, adding value to the company’s assets and bringing us closer to the point where our clinical programs for VAL401 will deliver meaningful data and will bring the company closer to finding a partner. I am pleased with the momentum generated as we move towards clinical development a milestones and potential value inflection points for VAL401 as we approach the year-end,” Oliver de Giorgio-Miller, Non-Executive Chairman.4